NASDAQ:AKRO - Akero Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $58.83
  • Forecasted Upside: 107.82 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$28.31
▲ +0.33 (1.18%)
1 month | 3 months | 12 months
Get New Akero Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKRO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$58.83
▲ +107.82% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Akero Therapeutics in the last 3 months. The average price target is $58.83, with a high forecast of $79.00 and a low forecast of $41.00. The average price target represents a 107.82% upside from the last price of $28.31.
Buy
The current consensus among 6 investment analysts is to buy stock in Akero Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/29/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2020HC WainwrightBoost Price TargetBuy$62.00 ➝ $64.00High
i
9/10/2020Morgan StanleyInitiated CoverageOverweight$70.00High
i
8/13/2020Chardan CapitalReiterated RatingBuyLow
i
Rating by M. Morabito at Chardan Capital
7/20/2020HC WainwrightBoost Price TargetBuy$45.00 ➝ $62.00High
i
Rating by E. Arce at HC Wainwright
7/7/2020Chardan CapitalInitiated CoverageBuy$79.00High
i
Rating by M. Morabito at Chardan Capital
7/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$28.00 ➝ $41.00High
i
7/1/2020Jefferies Financial GroupBoost Price TargetBuy$31.00 ➝ $48.00High
i
7/1/2020Canaccord GenuityBoost Price TargetBuy$36.00 ➝ $51.00High
i
Rating by Edward Nash at Canaccord Genuity
7/1/2020HC WainwrightBoost Price TargetBuy$33.00 ➝ $45.00High
i
Rating by E. Arce at HC Wainwright
6/18/2020Canaccord GenuityReiterated RatingBuyMedium
i
Rating by Edward Nash at Canaccord Genuity
3/18/2020Canaccord GenuityReiterated RatingBuyHigh
i
Rating by Edward Nash at Canaccord Genuity
3/2/2020HC WainwrightInitiated CoverageBuy$33.00High
i
Rating by E. Arce at HC Wainwright
2/10/2020Canaccord GenuityInitiated CoverageBuy$36.00Medium
i
7/15/2019Evercore ISIInitiated CoverageOutperform ➝ Outperform$35.00Low
i
7/15/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$28.00High
i
7/15/2019Roth CapitalInitiated CoverageBuy ➝ Buy$34.00High
i
Rating by Y. Rahimi at Roth Capital
7/15/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$28.00High
i
(Data available from 11/25/2015 forward)
Akero Therapeutics logo
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $28.31
$27.40
$28.54

50 Day Range

MA: $27.95
$25.80
$29.89

52 Week Range

Now: $28.31
$10.78
$41.16

Volume

114,352 shs

Average Volume

238,663 shs

Market Capitalization

$982.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65